MicroRNA‑183 inhibits A375 human melanoma cell migration and invasion by targeting Ezrin and MMP‑9
- Authors:
- Yusen Zhang
- Guoqiang Wang
-
Affiliations: Department of Plastic Surgery, People's Hospital of Zhengzhou, Henan Agricultural University, Zhengzhou, Henan 450000, P.R. China, Key Laboratory of Animal Biochemistry and Nutrition, Ministry of Agriculture, Henan Agricultural University, Zhengzhou, Henan 450000, P.R. China - Published online on: October 22, 2018 https://doi.org/10.3892/ol.2018.9603
- Pages: 548-554
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al: Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 109:2017. View Article : Google Scholar | |
|
Nikolaou V and Stratigos AJ: Emerging trends in the epidemiology of melanoma. Br J Dermatol. 170:11–19. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Damsky WE, Theodosakis N and Bosenberg M: Melanoma metastasis: New concepts and evolving paradigms. Oncogene. 33:2413–2422. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr and Slominski A: Current concepts of metastasis in melanoma. Expert Rev Dermatol. 3:569–585. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen DX, Bos PD and Massagué J: Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bravo-Cordero JJ, Hodgson L and Condeelis J: Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 24:277–283. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Long ZY and Wang TH: Advances of the role of Ezrin in migration and invasion of breast cancer cells. Sheng Li Ke Xue Jin Zhan. 47:21–26. 2016.(In Chinese). PubMed/NCBI | |
|
Liu HY, Gu WJ, Wang CZ, Ji XJ and Mu YM: Matrix metalloproteinase-9 and −2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials. Medicine. 95:e39042016. View Article : Google Scholar : PubMed/NCBI | |
|
Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G, Cervello M, Polesel J, et al: Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta. 1863:438–448. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pârvănescu V, Georgescu M, Georgescu I, Șurlin V, Pătraşcu Ș, Picleanu AM and Georgescu E: The role of matrix metalloproteinase-9 (MMP-9) as a prognostic factor in epithelial and lymphatic neoplasia. Chirurgia. 110:506–510. 2015.PubMed/NCBI | |
|
Li J, Wei K, Yu H, Jin D, Wang G and Yu B: Prognostic value of Ezrin in various cancers: A systematic review and updated meta-analysis. Sci Rep. 5:179032015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao DH, Zhu J, Wang WB, Dong F, Zhang Q, Fan HW, Zhang JZ and Wang YM: Correlations of ezrin expression with pathological characteristics and prognosis of osteosarcoma: A meta-analysis. ScientificWorldJournal. 2014:8375432014. View Article : Google Scholar : PubMed/NCBI | |
|
Choi SD, Fadiel A and Naftolin F: Erratum to: Ezrin is an essential marker for metastasis of gynecologic cancer. J Menopausal Med. 22:1882016. View Article : Google Scholar | |
|
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 10:182–186. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Korkeila EA, Syrjänen K, Bendardaf R, Laulajainen M, Carpén O, Pyrhönen S and Sundström J: Preoperative radiotherapy modulates ezrin expression and its value as a predictive marker in patients with rectal cancer. Hum Pathol. 42:384–392. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Patara M, Santos EM, de Almeida Coudry R, Soares FA, Ferreira FO and Rossi BM: Ezrin expression as a prognostic marker in colorectal adenocarcinoma. Pathol Oncol Res. 17:827–833. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ilmonen S, Vaheri A, Asko-Seljavaara S and Carpen O: Ezrin in primary cutaneous melanoma. Mod Pathol. 18:503–510. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bretscher A, Edwards K and Fehon RG: ERM proteins and merlin: Integrators at the cell cortex. Nat Rev Mol Cell Biol. 3:586–599. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
McClatchey AI: Merlin and ERM proteins: Unappreciated roles in cancer development? Nat Rev Cancer. 3:877–883. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Feng YM and Fang SQ: Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 50:e53562017. View Article : Google Scholar : PubMed/NCBI | |
|
Horwitz V, Davidson B, Stern D, Trope CG, Tavor Re'em T and Reich R: Ezrin is associated with disease progression in ovarian carcinoma. PLoS One. 11:e01625022016. View Article : Google Scholar : PubMed/NCBI | |
|
Kong J, Di C, Piao J, Sun J, Han L, Chen L, Yan G and Lin Z: Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget. 7:19631–19642. 2016.PubMed/NCBI | |
|
McRobert EA and Bach LA: Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products. Nephrology. 21:13–20. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Piao J and Liu S, Xu Y, Wang C, Lin Z, Qin Y and Liu S: Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Exp Mol Pathol. 98:1–6. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Lin Z, Chen B, Chen S, Jiang Z, Zhou T, Hou Z and Wang Y: Ezrin/NF-κB activation regulates epithelial-mesenchymal transition induced by EGF and promotes metastasis of colorectal cancer. Biomed Pharmacother. 92:140–148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
He J, Ma G, Qian J, Zhu Y, Liang M, Yao N, Ding Q, Chen L, Liu X, Xia T, et al: Interaction between ezrin and cortactin in promoting epithelial to mesenchymal transition in breast cancer cells. Med Sci Monit. 23:1583–1596. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lan M, Kojima T, Murata M, Osanai M, Takano K, Chiba H and Sawada N: Phosphorylation of ezrin enhances microvillus length via a p38 MAP-kinase pathway in an immortalized mouse hepatic cell line. Exp Cell Res. 312:111–120. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dang B, Duan X, Wang Z, He W and Chen G: A therapeutic target of cerebral hemorrhagic stroke: Matrix metalloproteinase-9. Curr Drug Targets. 18:1358–1366. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Boziki M and Grigoriadis N: An update on the role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Med Chem. 14:155–169. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Banday MZ, Sameer AS, Mir AH, Mokhdomi TA, Chowdri NA and Haq E: Matrix metalloproteinase (MMP) −2, −7 and −9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review. Gene. 589:81–89. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gong L, Wu D, Zou J, Chen J, Chen L, Chen Y, Ni C and Yuan H: Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget. 7:18458–18468. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yonemori K, Kurahara H, Maemura K and Natsugoe S: MicroRNA in pancreatic cancer. J Hum Genet. 62:33–40. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xue J, Yang J, Luo M, Cho WC and Liu X: MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opin Drug Discov. 12:141–157. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Manasa VG and Kannan S: Impact of microRNA dynamics on cancer hallmarks: An oral cancer scenario. Tumour Biol. 39:10104283176959202017.doi: 10.1177/1010428317695920. View Article : Google Scholar : PubMed/NCBI | |
|
Latchana N, Ganju A, Howard JH and Carson WE III: MicroRNA dysregulation in melanoma. Surg Oncol. 25:184–189. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanekura K, Nishi H, Isaka K and Kuroda M: MicroRNA and gynecologic cancers. J Obstet Gynaecol Res. 42:612–617. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
D'Angelo B, Benedetti E, Cimini A and Giordano A: MicroRNAs: A puzzling tool in cancer diagnostics and therapy. Anticancer Res. 36:5571–5575. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lima CR, Gomes CC and Santos MF: Role of microRNAs in endocrine cancer metastasis. Mol Cell Endocrinol. 456:62–75. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Moridikia A, Mirzaei H, Sahebkar A and Salimian J: MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J Cell Physiol. 233:901–913. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM, Sun Y and Chen XF: Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget. 7:42805–42825. 2016.PubMed/NCBI | |
|
Shimono Y, Mukohyama J, Nakamura S and Minami H: MicroRNA regulation of human breast cancer stem cells. J Clin Med. 5(pii): E22015. View Article : Google Scholar : PubMed/NCBI | |
|
Dambal S, Shah M, Mihelich B and Nonn L: The microRNA-183 cluster: The family that plays together stays together. Nucleic Acids Res. 43:7173–7188. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wojtas B, Ferraz C, Stokowy T, Hauptmann S, Lange D, Dralle H, Musholt T, Jarzab B, Paschke R and Eszlinger M: Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol. 388:1–9. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, Tang ZH and Huang F: Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene. 527:26–32. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan H, Liang X, Zhao W, Ma L and Zhao Y: The effects of microRNA-183 promots cell proliferation and invasion by targeting MMP-9 in endometrial cancer. Biomed Pharmacother. 89:812–818. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X, Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor via inhibiting cellular invasion and metastasis by targeting MMP-9 in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Zuo J, Lei M, Wu S, Zang X and Zhang C: Ezrin promotes invasion and migration of the MG63 osteosarcoma cell. Chin Med J. 127:1954–1959. 2014.PubMed/NCBI | |
|
Mu Y, Zhang H, Che L and Li K: Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol. 31:8212014. View Article : Google Scholar : PubMed/NCBI | |
|
Cao LL, Xie JW, Lin Y, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY and Huang CM: miR-183 inhibits invasion of gastric cancer by targeting Ezrin. Int J Clin Exp Pathol. 7:5582–5594. 2014.PubMed/NCBI | |
|
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X and Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Mao W and Zheng S: MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 582:3663–3668. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu YY, Shi GY, Kuo CH, Liu SL, Wu CM, Ma CY, Lin FY, Yang HY and Wu HL: Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration. FASEB J. 26:3440–3452. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Brambilla D and Fais S: The Janus-faced role of ezrin in ‘linking’ cells to either normal or metastatic phenotype. Int J Cancer. 125:2239–2245. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Federici C, Brambilla D, Lozupone F, Matarrese P, de Milito A, Lugini L, Iessi E, Cecchetti S, Marino M, Perdicchio M, et al: Pleiotropic function of ezrin in human metastatic melanomas. Int J Cancer. 124:2804–2812. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kim A, Im M, Yim NH and Ma JY: Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production. Sci Rep. 4:69942014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KR, Lee JS, Kim YR, Song IG and Hong EK: Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-κB signaling pathway. Oncol Rep. 31:2447–2453. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tang ZY, Liu Y, Liu LX, Ding XY, Zhang H and Fang LQ: RNAi-mediated MMP-9 silencing inhibits mouse melanoma cell invasion and migration in vitro and in vivo. Cell Biol Int. 37:849–854. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung CC, Lun SW, Chung GT, Chow C, Lo C, Choy KW and Lo KW: MicroRNA-183 suppresses cancer stem-like cell properties in EBV-associated nasopharyngeal carcinoma. BMC Cancer. 16:4952016. View Article : Google Scholar : PubMed/NCBI | |
|
Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, Li S, Tang H and Xie X: High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep. 6:245022016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu C, Deng X, Wu J, Zhang J, Yang H, Fu S, Zhang Y, Han Y, Zou Y, Chen Z, et al: MicroRNA-183 promotes migration and invasion of CD133+/CD326+ lung adenocarcinoma initiating cells via PTPN4 inhibition. Tumour Biol. 37:11289–11297. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Miao F, Zhu J, Chen Y, Tang N, Wang X and Li X: MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett. 11:134–140. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu F, Zhang H, Su Y, Kong J, Yu H and Qian B: Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clin Transl Oncol. 16:980–985. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou T, Zhang GJ, Zhou H, Xiao HX and Li Y: Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 26:229–233. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z and Zhu Q: MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. Breast Cancer Res. 16:4732014. View Article : Google Scholar : PubMed/NCBI | |
|
Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M, Bai AH, et al: Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 123:539–552. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li ZB, Li ZZ, Li L, Chu HT and Jia M: MiR-21 and miR-183 can simultaneously target SOCS6 and modulate growth and invasion of hepatocellular carcinoma (HCC) cells. Eur Rev Med Pharmacol Sci. 19:3208–3217. 2015.PubMed/NCBI | |
|
Yang M, Liu R, Li X, Liao J, Pu Y, Pan E, Yin L and Wang Y: miRNA-183 suppresses apoptosis and promotes proliferation in esophageal cancer by targeting PDCD4. Mol Cells. 37:873–880. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang H, Li X and Xia J: MicroRNA-183 functions as an oncogene by regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem. 16:447–455. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YY and Feng HM: MEG3 suppresses human pancreatic neuroendocrine tumor cells growth and metastasis by down-regulation of Mir-183. Cell Physiol Biochem. 44:345–356. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sarver AL, Li L and Subramanian S: MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 70:9570–9580. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yang CL, Zheng XL, Ye K, Ge H, Sun YN, Lu YF and Fan QX: MicroRNA-183 acts as a tumor suppressor in human non-small cell lung cancer by down-regulating MTA1. Cell Physiol Biochem. 46:93–106. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao P, He M, Zhang C and Geng C: Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene. 654–695. 2018. | |
|
Li J, Liang S, Jin H, Xu C, Ma D and Lu X: Tiam1, negatively regulated by miR-22, miR-183 and miR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol Rep. 27:18352012.PubMed/NCBI |
